Acknowledgements Funding The study and the Rapid Service Fee was supported by funding from Novo Nordisk A/S, which provided consulting fees to Ossian Health Economics and Communications, Basel, Switzerland
Clinical studies show that patients on GLP-1 therapy experience modest reductions in resting metabolic rate, typically 515%
Peaks async model trades clinical screening for speed, which works well for buyers who already understand GLP-1 treatment and want medication fast, less so for anyone who wants a clinician to review baseline labs first
This is a preview of subscription content, access via your institution Access options Subjects References Unger, R.H
Exceptions: self-funded employer groups that opted in, Michigan Medicaid (which covers Wegovy as a preferred anti-obesity medication with PA and quantity limits for ages 12 and older), and Medicare (cardiovascular indication only)